In 2024 , MJFF launched a $ 30 million program focused on bringing the most promising research from the laboratory to the therapeutic pipeline .
ADVANCING BETTER TREATMENTS FOR ALL STAGES OF PARKINSON ’ S
THE MICHAEL J . FOX FOUNDATION 2024 YEAR IN REVIEW to bring a single treatment to market is a daunting reality for biotechnology and pharmaceutical companies , as the vast majority of experimental therapies fail in clinical testing ( especially in the absence of a biomarker , which is why the advent of aSyn-SAA is so momentous ). This in turn tends to have the effect of lessening industry investment in Parkinson ’ s R & D .
In recognition of this challenge , MJFF employs de-risking to lower barriers to companies in the brain disease space . Our donor-raised capital provides support — in the form of both funding and collaborative assistance — for the earliest stages of promising therapeutic development programs . The goal is to make drug developer investment in novel therapies more attractive and less risky .
In 2024 , MJFF launched a $ 30 million program focused on bringing the most promising research from the laboratory to the therapeutic pipeline .
MJFF ’ s support for early research has repeatedly led to biotech acquisition by larger pharmaceutical drug developers with greater resources to take a treatment the rest of the way to market . In 2024 , the Foundation ’ s de-risking approach enabled AbbVie ’ s acquisition of two MJFF-supported partners and Merck ’ s acquisition of another . All three of the acquired companies have developed earlystage therapies that show promise to slow or stop the progression of PD .
To further advance this work , with leadership philanthropic support from an anonymous donor , MJFF launched a $ 30 million program in 2024 that is entirely focused on ensuring the most promising pre-clinical research gets translated from the laboratory into the therapeutic pipeline .
23